Invasive Pneumococcal Disease Surveillance, 1 July to 30 September 2018

被引：0

作者：

Pennington, Kate

Beard, Frank ^{[1
]}

Boyd, Rowena

Cook, Heather

Franklin, Lucinda

Giele, Carolien

Gilmour, Robin

Harlock, Michelle

Howden, Ben ^{[2
]}

Jayasinghe, Sanjay ^{[1
]}

Krause, Vicki

Oftadeh, Shahin ^{[3
]}

Reid, Sue

Sintchenko, Vitali ^{[4
]}

Smith, Helen ^{[5
]}

Strachan, Janet

Vogt, Hannah

Wakefield, Angela

机构：

[1] NCIRS, Westmead, NSW, Australia

[2] Univ Melbourne, Microbiol Diagnost Unit, Melbourne, Vic, Australia

[3] NSW Hlth Pathol, Ctr Infect Dis & Microbiol Lab Serv, Newcastle, NSW, Australia

[4] Westmead Hosp, Ctr Infect Dis & Microbiol Publ Hlth, Westmead, NSW, Australia

[5] Queensland Hlth Forens & Sci Serv, Coopers Plains, Australia

来源：

COMMUNICABLE DISEASES INTELLIGENCE | 2019年 / 43卷

关键词：

D O I：

10.33321/cdi.2019.43.57

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The number of notified cases of invasive pneumococcal disease (IPD) in the third quarter of 2018 was greater than the previous quarter, but lower than the third quarter of 2017. Following the July 2011 replacement of the 7-valent pneumococcal conjugate vaccine (7vPCV) in the childhood immunisation program with the 13-valent pneumococcal conjugate vaccine (13vPCV), there was an initial relatively rapid dedine in disease due to the additional six serotypes covered by the 13vPCV across all age groups; however, more recently this decline is no longer evident. Over this period the number of cases due to the eleven serotypes additionally covered by the 23-valent pneumococcal polysaccharide vaccine (23vPPV), and also those serotypes not covered by any available vaccine, has been increasing steadily across all age groups (Figure 1).

引用

页数：12